Cerus Corporation (CERS)
| Market Cap | 395.73M |
| Revenue (ttm) | 206.13M |
| Net Income (ttm) | -15.63M |
| Shares Out | 200.37M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 494,094 |
| Open | 1.970 |
| Previous Close | 1.980 |
| Day's Range | 1.930 - 1.990 |
| 52-Week Range | 1.150 - 2.955 |
| Beta | 1.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do... [Read more]
Financial Performance
In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.
Financial StatementsNews
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establis...
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the st...
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effe...
Cerus Transcript: TD Cowen 46th Annual Health Care Conference
INTERCEPT Blood System continues to expand its global leadership in transfusion safety, leveraging strong U.S. and international growth, a robust product pipeline, and strategic partnerships like the BCA agreement. Double-digit revenue growth is expected through 2026, with new product launches and geographic expansion driving future gains.
Cerus Earnings Call Transcript: Q4 2025
Record 2025 revenue and product growth were driven by strong U.S. and EMEA performance, successful INT200 launch, and expanding IFC adoption. 2026 guidance projects continued revenue and EBITDA growth, with BCA agreement and international expansion as key drivers.
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our ...
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference ...
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of...
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its sub...
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guida...
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply c...
Cerus Earnings Call Transcript: Q3 2025
Record Q3 revenue grew 15% year-over-year, driven by strong platelet and IFC sales. Full-year guidance was raised, margins faced some headwinds, and the shift to IFC kit sales is expected to further improve profitability. Positive outlook continues into 2026.
Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. “We continue to mak...
Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commo...
Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the ...
Cerus Transcript: Cantor Global Healthcare Conference 2025
INTERCEPT Blood Systems is expanding globally, with strong financial growth, increased guidance, and new product launches like IFC. Regulatory progress continues for red blood cells, while operational efficiencies and government funding support future expansion.
The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Bl...
Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednes...
Cerus Earnings Call Transcript: Q2 2025
Record Q2 revenue and strong IFC demand led to raised 2025 guidance and fifth straight positive adjusted EBITDA quarter. Growth was broad-based across geographies and products, with new launches and regulatory progress supporting future expansion.
Cerus Corporation Announces Second Quarter 2025 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to ad...
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the st...
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Indust...
Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory rev...
Cerus Corporation Celebrates World Blood Donor Day 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World ...
Cerus Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
INTERCEPT technology is the global standard for platelet safety, driving recurring revenue and market leadership. New product innovations and expanding clinical data support strong financial growth, with major opportunities in red cells and fibrinogen complex ahead.